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Numerous reviews have discussed gut microbiota composition changes during inflam-
matory bowel diseases (IBD), particularly Crohn’s disease (CD). However, most studies 
address the observed effects by focusing on studying the univariate connection between 
disease and dietary-induced alterations to gut microbiota composition. The possibility 
that these effects may reflect a number of other interconnected (i.e., pantropic) mech-
anisms, activated in parallel, particularly concerning various bacterial metabolites, is 
in the process of being elucidated. Progress seems, however, hampered by various 
difficult-to-study factors interacting at the mucosal level. Here, we highlight some of 
such factors that merit consideration, namely: (1) the contribution of host genetics and 
diet in altering gut microbiome, and in turn, the crosstalk among secondary metabolic 
pathways; (2) the interdependence between the amount of dietary fat, the fatty acid 
composition, the effects of timing and route of administration on gut microbiota commu-
nity, and the impact of microbiota-derived fatty acids; (3) the effect of diet on bile acid 
composition, and the modulator role of bile acids on the gut microbiota; (4) the impact of 
endogenous and exogenous intestinal micronutrients and metabolites; and (5) the need 
to consider food associated toxins and chemicals, which can introduce confounding 
immune modulating elements (e.g., antioxidant and phytochemicals in oils and proteins). 
These concepts, which are not mutually exclusive, are herein illustrated paying special 
emphasis on physiologically inter-related processes.
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iNTRODUCTiON
Inflammatory bowel diseases (IBD) are chronic, inflammatory disorders of the gastrointestinal 
tract that develop as a result of a deregulation of the T cell-mediated immune responses toward 
the intestinal bacteria. Attenuated response to pathogen recognition and clearance facilitated by 
impaired mucus barrier function, as a result of a bacterially driven, aberrant immune-mediated 
response in genetically susceptible hosts, are all characteristic of IBD (1–4). The inflammatory 
response is a critical component to host survival, particularly during infection; however, the 
specific nature of immune response, which is initiated by the host to eradicate the infectious 
invader, depends on the type of pathogen, and thus factors such as pathogen localization (intracel-
lular, extracellular) and endotoxins contained within pathogens [e.g., lipopolysaccharide (LPS), 
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and lipoteichoic acid] or exotoxins secreted by pathogens (e.g., 
Staphylococcus aureus, Streptococcus pyogenes) (5,  6), may 
have direct and indirect consequences on the severity and 
maintenance of host inflammatory responses to pathogenic and 
commensal bacteria (7). Intracellular pathogens and all viruses 
activate professional phagocytes and generation of cytotoxic 
T-lymphocytes, whereas pathogen-specific antibodies are 
required for extracellular pathogens.
To date, it is unclear to what extent the inflammatory response 
in IBD is due to host inflammatory reactivity to gut local 
microbial molecules, or whether the changes observed in the 
gut microbiota (dysbiosis) are a consequence reflecting the level 
of intestinal inflammaton. Host tissue damage is an indirect 
consequence of the natural cascades initiated by host inflamma-
tory responses, which may derive from exposure to uncontrolled 
concentrations of LPS. Toll-like receptor 4 (TLR4), stimulated 
by soluble LPS, activates intracellular signaling that results in 
nuclear factor-kappa beta (NF-kB) activation, and subsequent 
production of interleukin-1beta (IL-1β), tumor necrosis factor 
beta (TNFβ), interleukin-6 (IL-6), and nitric oxide synthase 
(iNOS) (8). Nitric oxide (NO) is synthesized from amino acid 
l-arginine, via nitric oxide synthases (NOS), can be generated 
by the inducible isoform of NOS (NOS-2 or iNOS) through a 
Ca2+-independent pathway (9). Herein, we present a synopsis 
of metabolic examples where mucosal interactions between 
genetics, diet, and microbiome may be relevant in triggering, 
modulating, or alleviating inflammation in so-called IBD from 
data available in murine models and in humans affected particu-
larly with CD.
GeNeTiCS AND GUT MiCROBiOTA
Theoretically, a healthy symbiotic host–microbe relationship is 
necessary for the normal development of gut mucosal immunity 
to maintain intestinal homeostasis and prevent excessive uncon-
trolled periods of local inflammation (10). The gut microbiota 
also prevents the colonization and virulence of pathogens, while 
promoting epithelial-barrier function, partly by promoting the 
renewal of epithelial cells. Host genetics and gene expression 
modulate immune mechanism of microbial molecular pattern 
recognition to influence the diversity and functionality of local 
microbiota (11). Since the discovery of the nucleotide oligomeri-
zation domain (NOD2) gene, numerous gene loci associated with 
abnormal innate immune responses (CARD15/NOD2, TLR4, 
CARD9, RAGE), differentiation of Th17-lymphocytes (IL-23R, 
JAK2, STAT3, CCR6, ICOSLG), autophagy (ATG16L1, IRGM, 
LRRK2, DEFB2/hBD2, SCL11A1), maintenance of epithelial 
barrier function (IBD5, DLG5, PTGER4, ITLN1, DMBT1, XBP1), 
and the initiation of secondary immune response (HLA-region, 
TNFSF15/TL1A, IRF5, PTPN2, PTPN22, NKX2-3, IL-12B, 
IL-18RAP, MST1) have been recognized for their role in CD 
pathogenesis (1, 2, 12–16). The discovery of novel susceptibil-
ity variants continues to grow (17, 18). Thus genetic alterations 
may influence immunity by either suppressing or promoting 
pathogenic microbial blooms, in turn, affecting epithelial-barrier 
integrity, host intestinal immunity and inflammation, all converg-
ing to regulate transient periods of susceptibility to IBD flare-ups.
iMMUNe CeLLS AND GUT MiCROBiOTA
Throughout the lifetime of an individual, the diversity and the 
composition of the microbiome are subject to change not only 
as a function of age but also of diet, environment (hygiene and 
demographics), and lifestyle (19, 20). The immunologic reac-
tiveness to dietary and microbial antigens locally is primarily 
tolerogenic; maintained by the innate immune system ability 
to recognize antigen patterns, which determines the level and 
direction of T cell reactivity (21–23). Intestinal macrophages 
sense and respond to intestinal microorganisms through pattern 
recognition receptors (PRRs), such as Toll-like receptors (TLRs) 
(24). T helper (Th) cells originally divided into Th1 and Th2 
subsets, have the Th1 cells as prime mediators of immunity to 
extracellular pathogens, due to their ability to secrete proinflam-
matory cytokine interferon gamma (INFy), which activates local 
and systemic macrophages (25). Complementary T cell subsets, 
proinflammatory Th17 (IL-17-secreting CD4+ T cell subset) and 
anti-inflammatory (tolerogenic to self-antigen and commensal 
bacteria) T regulatory cells (Tregs) (forkhead box P3; Foxp3) 
contribute to that balance (26, 27).
In the gut, Tregs function to suppress the proliferation and 
effector functions of other T cells, with imbalances between Treg 
and Th17 cells playing an intricate role in T cell-mediated inflam-
matory disorders, and also microbial immunity (26). Although 
Tregs and Th17 cells differentiate from the same T cell precursor 
(naïve T cells) pool, in murine models, it is the transforming 
growth factor (TGF-β) in the presence of retinoic acid, which 
drives differentiation to Tregs, whereas Th17 cells result from 
collective activity of TGF-β and IL-6, which in humans also 
necessitates IL-21 (28–31).
CD4+ T cells orchestrate pro- and anti-inflammatory immune 
responses, but this balance depends on naive CD4+ T cells differ-
entiation into functionally distinct regulatory or effector subsets 
in secondary lymphoid organs (i.e., spleen, lymph nodes) (32). 
New data have expanded the CD4+ T cell differentiation frame-
work to include Foxp3-independent activation of the CD4+ T cell 
regulatory axis via IL-27, a differentiation factor for regulatory 
type 1 cells (Tr1), a major class of IL-10 producing CD4+ T cells 
with important immunosuppressive functions, which lack Foxp3 
expression (33). Folicular T helper cells (Tfh) also influence the 
CD4+ T cell balance by migrating from the T cell area to the B cell 
follicle via CCR7 downregulation and concurrent expression of 
homing chemokine receptor CXCR5 (34, 35), a crosstalk pro-
moted by Tfh production of IL-21 through transcription factor 
BCL-6, which also promotes the Th1/Th17 profile (32). The BCL2 
pathway has been implicated in STAT factors induced by IL-6 
that in turn promotes IL-21 and TNFα production, and Th1-
differentiated cells can adopt a Tfh-like phenotype by interacting 
with STAT proteins and downregulating BLIMP1 in the presence 
of IL-2 (36). Finally, discovery of the Th9 phenotype, via IL-9 
produced by the transcription factor PU.1, and also the Th22 
phenotype, via IL-22 produced by the aryl hydrocarbon receptor 
(AhR), suggests that CD4+ T cell populations are highly hetero-
geneous in nature. Delineation of this wide biological complexity 
is now commanding the implementation of computational mod-
eling (37–39) as novel tools to describe the differentiation process 
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of immune cell types, simulate their interplay between intricate 
pathways in context to immune-mediated disorders and also diet, 
synthesize, and advance novel hypotheses (32).
Computational Biology and 
Mathematical Modeling
If microbial dynamics are host specific, mathematical-based 
predictive strategies could be used for interventions modulating 
microbiota. Conversely, some interactions between gut microbial 
communities may be found universal, i.e., consistent across hosts. 
Knowledge of such parameters could be combined across differ-
ent studies making it useful for the development of common 
mathematical models (40). An example of such development 
includes the elegant use of dissimilarity-overlap curve (DOC) 
tests, which have been useful to assess, for instance, whether 
microbial communities within a specific body part have the 
same underlying dynamics across individuals (41), and whether 
subjects with reccurent Clostridiun difficile infection have com-
parable gut microbial behavior before and after fecal material 
transplantation (FMT) (41).
Modeling systems enabled for the study of mucosal and 
nutritional immunology have been recently reviewed (32, 39). In 
brief, primary examples of successfully implemented modeling 
approaches are the Modeling Immunity to Enteric Pathogens 
project (MIEP) and the Nutritional Immunology and Molecular 
Medicine Laboratory. In an elaborate series of experiments that 
included computational-based drug design methods, biochemi-
cal and in vivo studies (42, 43), MIEP identified the lanthionine 
sythetase component cyclase-like protein (LANCL2), a molecu-
lar target of abscisic acids, a plant phytohormone with insulin-
sensitizing (44–46) and immunomodulatory actions (47–49), as 
a target for drug development against inflammatory, immune-
mediated, and metabolic disease (50). Following the validation 
of these results in experimental IBD mouse models, MIEP 
formulated these preliminary results into advanced machine-
learning algorithms to design a Phase III clinical in  silico trial 
comprised of synthetically generated CD patients (51). Other 
notable MIEP-based acheivements include the development of 
validated computational models of CD4+ T cell differentiation 
and function (32, 43, 52), and the characterization of CD4+ T cell 
(via IL-21) (43) and mucosal immune responses to Helicobacter 
pylori infection (53).
GUT MiCROBiOTA CHANGeS iN iBD
Several reviews have discussed the role of microbiota on gut 
immunology, and how genetically encoded mechanisms can shape 
the composition of the intestinal microbiome (11). Discussions 
are available on the role of the human gut microbiome in the 
pathogenesis of IBD, and on the emerging patterns of reduced 
microbial diversity and imbalances (i.e., “dysbiosis”) that occurs 
in IBD (10, 54), and in twins discordant for CD (20, 55–59).
Such patterns include a reduction in the number of several 
microbial species within the phylum Firmicutes, specifically 
the Clostridium clusters XIVa and IV as observed in CD, while 
Bacillus spp increase (10, 54, 58, 60–62). As a commensal species, 
Clostridium clusters XIVa and IV induce colonic Tregs (63), 
preventing the development of excessive inflammation, a process 
that seems facilitated by high local concentrations of TGF-β (64). 
Proteobacteria, particularly the presence of Escherichia coli (mainly 
AIEC) is higher in IBD (65–67), compared with healthy controls 
(59, 68). Enterobacteriacae are one of the families consistently 
increased within the Proteobacteria phylum in IBD, while reduc-
tions in Bifidobacterium, Lactobacillus, and Ruminococcaceae 
(particularly the butyrate-producing genus Faecalibacterum) 
are decreased within the Bacteroidetes phylum in ileal CD (69). 
Faecalibacterum prausnitzii has anti-inflammatory properties, 
and low abundances have being associated with higher risk for 
repeated CD surgery (70, 71). Differences in fungal (72, 73) and 
viral diversity (74) are also observed in CD patients, with more 
bacteriophages especially in non-ulcerated mucosa samples of 
CD patients (75).
Animal studies illustrate the role of genetic–virus interaction in 
CD. In conventional mice, the genetic–virus interaction between 
ATG16L1 and norovirus infection is required for CD-like onset 
(76), whereas mice lacking Dectin1 had increased susceptibility to 
chemically induced colitis due to altered responses to indigenous 
fungi, namely Candida tropicalis, which is also common in the 
stools of humans (77). Interestingly, a polymorphism in Dectin1 
(CLEC7A) was associated with severe ulcerative colitis (UC) in 
humans (77, 78). Metagenomics have also identified functional 
differences in up to 12% of metabolic pathways of active IBD 
patients compared to controls, despite only the 2% genus-level 
changes observed in stool and intestinal biopsies specimens (69). 
No metabolic studies are available in mice affected by spontane-
ous forms of IBD (79, 80).
iNTeSTiNAL AND ADiPOSiTY 
CONSTRAiNS ON MiCROBiAL 
ABUNDANCe
Microbial colonization occurs from mouth to anus, although 
density and composition varies by location, intestinal transit rate, 
host secretions, environment, availability of dietary substrates, and 
intestinal structures. The acidic environment in the stomach limits 
bacterial growth mostly to H. pylori, but bacterial species progres-
sively increase within the ileum, which is mainly colonized by 
Enterobacteria, Bacteriodes, and Clostridia (81). The colon (lowest 
pH) provides a favorable environment for anaerobic microbial 
growth where organisms harvest energy via host-derived nutrients 
from secreted mucin (mucus) and fermentation of non-digested 
dietary fibers. This results in the production of short chain fatty 
acids (SCFAs), acetate, propionate and butyrate, and also the 
gasses hydrogen (H2), carbon dioxide (CO2), methane (CH4), and 
hydrogen sulfide (H2S) (81). These factors alter intestinal motil-
ity and inflammation, mechanisms that can influence locally the 
mucosa or the enteric nervous and muscle system (82–84).
Despite the fact that more than sixty phyla exist in the 
bacterial world, in fecal samples of healthy human volunteers 
(85–87), two phyla, Firmicutes (~65%) and Bacteroidetes 
(~25%) (88), comprise most of the microbial species detected, 
suggesting that microbiota composition is subject to strong 
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constraints (81). The remaining species belong to the phyla 
Actinobacteria (e.g., Bifidobacterium spp.), Proteobacteria 
(e.g., E. coli), Verrucomicrobia (e.g., Akkermansia mucin-
iphilia), Fusobacteria, and Cyanobacteria (89), all capable of 
mediating metabolic conditions (obesity, diabetes) and local 
intestinal inflammation. Based on health status and diet, fecal 
metagenomic data have been used since 2010 (90) to classify 
human intestinal phenotypes into three broadly defined “ente-
rotypes.” The hallmark for differentiation is genus dominance of 
Prevotella, Bacteroides, or Ruminococcus (91), but Ruminococcus 
can be subdivided by genus abundance of methane-producing 
Methanobrevibacter (92). Despite progress in this field, it is 
increasingly evident that intestinal microbial pattern phenotyp-
ing is rather more complex.
Body mass as surrogate for cumulative adiposity also seems 
to correlate with gut microbiota diversity and richness, although 
microbiome meta-analysis indicates that early findings are largely 
inconsistent. More predictability (less study-to-study variability) 
has been identified for IBDs. Individually, studies suggest that 
obesity correlates with an increased Firmicutes: Bacteroidetes 
ratio at the phylum level (93–99), and that FMT shifts the recipient 
gut microbiota profile based on the obesity-associated phenotype 
of the donor, both in humans and animals (100–102). Adipose 
tissue has been established to have a pro-inflammatory role (103, 
104) via its function as endocrine tissue, secreting proteins, such 
as leptin, cytokines and chemokines (105). However, significant 
differences exist between subcutaneous and visceral fat tissue 
in how gene expression is modulated (106–111), particularly of 
inflammatory pathways (109, 110, 112–115). Transcriptomics 
have shown that dietary interventions for weight-loss returns 
the equilibrium between pro- and anti-inflammatory factors by 
macrophages of visceral adipose tissue origin, in that production 
of pro-inflammatory cytokines (e.g., tumor necrosis factor alpha; 
TNFα) reduce, while anti-inflammatory molecules (IL-10 and 
IL1-Ra) increase (108, 116, 117). Plasma levels of these proteins 
seem to reflect dietary interventions concerning weight loss or 
weight gain (118), with weight loss being induced by a very-low 
calorie diet and alterations in expression of dozens of genes 
(108), alterations expected to result in changes of local microbial 
abundance.
Compared to non-obese counterparts, one metagenome study 
found that obese humans share an inflammatory enterotype, 
having a higher prevalence of IBD-associated Bacteroides genus 
and R. gnavus species (119–122). Consequently, sub-division of 
microbiota diversity has been proposed, on the basis of bacterial 
genome diversity, termed “low gene count” and “high gene count” 
(119). Key metabolites associated with low gene count bacteria 
include modules for degradation of aromatic amino acids, 
β-glucuronide degradation, and dissimilatory nitrate reduction 
(direct reduction from nitrate to ammonium), all of which have 
deleterious effects on intestinal mucosa. There is now evidence 
that Type-2 Diabetes in humans, a condition often accompanied 
by overweight and obesity, is associated with microbial shifts 
portrayed by decreased Roseburia intestinalis, F. prausnitzii, and 
Akkermansia municiphila (123–126). Identified for its protec-
tive effects, A. mucinphila is a novel mucin-degrading bacterial 
species, which vastly colonize the mucus layer localized at the 
epithelial surface of the ileum and colon (127). Higher levels 
of the bacterium positively correlate to glucagon-like peptide 2 
(GLP-2) levels, involved in gut barrier function (128). A num-
ber of murine studies have shown prebiotic (non-digestible 
carbohydrates) feeding favors A. mucinphila, improved gut 
barrier function, mucus layer thickness, and locally produced 
antimicrobials, including regenerating islet-derived 3-gamma 
(Reg3y) proteins (128–133). Strong evidence also exists to link 
the gut virome (early infections with enteric viruses) to the 
growing incidence of Type-1 diabetes in humans. Primarily 
driven by autoimmunity againt pancreatic cells, such enteric 
viral hypothesis, based on the type of virus and host genetics, 
can also intriguingly be protective (134–136).
Obviously, our understanding of host-regulated microbial 
abundances, the gut mucosa, and local virome is limited 
(Figure  1). Secretory IgA seems to be one increasingly under-
stood mechanism to modulate bacterial abundance (137–140). 
Other multivariable interactions need to be elucidated to enable 
the use of therapeutic strategies to decrease the severity of IBD 
and metabolic conditions characterized by microbe-driven pro-
inflammatory responses.
DieTARY FATTY ACiDS
Clinically known as triglycerides, fats are the storage form of 
fatty acids, which differ in chemical structure. Depending on 
chemical structure, fatty acids influence membrane structure and 
fluidity (141, 142) and many are directly involved in intracel-
lular signaling pathways, including receptor operated calcium 
channels (143), a key component in intracellular free calcium 
concentrations (144).
SHORT-CHAiN FATTY ACiDS
Of all components of the human diet, fats are generally believed 
to be associated with worsening of symptoms in IBD (145), 
despite the fact that dietary fats comprise diverse kinds of fatty 
acids [the basic molecules of fat, linear chains of carbon (C) 
surrounded by hydrogen]. Fatty acids can be classified as short-
chain (<6 carbons, SCFA), medium-chain (6–12, MCFA), long-
chain (12–21, LCFA), or very long chain (>22, VLCFA) fatty 
acids. Fatty acids also differ in the presence/absence of double 
carbon-to-carbon C:C bonds. Those without double C:C bonds 
are called saturated fatty acids (SFA), whereas one double bond 
is unsaturated (UFA), and more than one is polyunsaturated 
(PUFA). Most SCFAs are naturally saturated and are bacterially 
derived from dietary fibers, not fats. Dietary fibers come from 
the indigestible part of plant foods and substantially contribute 
to fecal SCFA concentrations, namely acetic acid (C2:0), propi-
onic acid (C3:0), and butyric acid (C4:0), traditionally referred 
to by their conjugate bases as acetate, propionate (also known 
as propanoate), and butyrate (also known as butanoate) in the 
salt form.
Depending on the chemical structure, fatty acids may be 
absorbed directly into the blood via the portal vein and trans-
ported to the liver, or actively via chylomicrons by transport 
mechanisms where they could interfere with gene expression, 
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FiGURe 1 | interactions between diet, gut microbiota, and the host within the intestinal lumen. Figure depicts an overview of the interconnected (pantropic) 
interactions between diet, gut microbiota and the host within the intestinal lumen.
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metabolic pathways of microbial metabolism, or community 
composition. LCFAs are absorbed as small bile-covered micelles 
by enterocytes in regions of the small intestine, although the 
portal route has been described (146). Once inside intestinal cells, 
micelles are re-esterified to chylomicrons, a mixture of lipids, pro-
teins, fat-soluble vitamins and cholesterol, surrounded by a lipo-
protein coat. Chylomicrons (lipoproteins) are first transported 
to the lymphatic system, and then the thoracic system, where 
they are carried to several tissues, including the liver. Because of 
their shorter chain length, MCFAs can be absorbed by mucosal 
cells without esterification and directly transported to the liver 
(bypassing lymphatic system), where they are metabolized into 
CO2, ketones, and acetate. The exception is lauric acid (C12:0), 
which undergoes similar digestion as LCFAs. By comparison, 
most SCFAs are generated and utilized within the gut, contribut-
ing to host immune responses, by regulating Tregs numbers and 
function (136, 147–152) via putative epigenetic Treg-associated 
transcription factors (153, 154). Only a small percent of SCFAs 
exist in the gut as unionized forms and can be absorbed via pas-
sive diffusion across the cell membrane, or actively in an ionized 
state mediated by receptors abundantly expressed in the intestinal 
tract (i.e., monocarboxylate transporter 1, MCT-1; and sodium-
coupled monocarboxylate transporter 1, SMCT-1) (155, 156). 
Alternatively, some acetate and propionate enter the portal blood 
to the liver, to be used in gluconeogenesis (155).
Regulation of colonic Tregs by SCFAs depends on the type 
of SCFA. Propionate and acetate mediate colonic migration of 
extraintestinal Tregs by upregulating G-protein coupled recep-
tors (GPCRs), namely GPR15 in a GPR43-dependant manner, 
whereas butyrate plays a central role in de novo generation of 
colonic Tregs (157) by facilitating naive CD4+ T cell differentia-
tion into Tregs via histone H3 acetylation in the promoter and 
CNS3 enhancer regulatory regions of Fox3p gene (149), or by 
altering the phenotype of dendritic cells (DCs) and inducing 
Treg differentiation via GPR109a activation (158–160). Histone 
deacetylates (HDACs) inhibition is also characteristic of butyrate, 
with HDAC9 inhibition shown to efficiently increase the prolif-
erative and functional capabilities of Tregs through increased 
Fox3p expression (151, 155, 161). In addition, butyrate-mediated 
HDAC inhibition may facilitate the anti-inflammatory response 
by active suppression of pro-inflammatory cytokine production 
in innate cells such as macrophages and DCs, mediated through 
modulation of NF-kB (150, 162). Of note, in vitro administration 
of butyrate to human Tregs moderately decreased Treg prolif-
eration, but increased their ability to inhibit T cell proliferation 
through a CTLA-4-mediated mechanism (152), with the inhibi-
tory activities of butyrate on HDAC shown to stimulate effector 
CD4+ T cells, independently of Tregs (163). These observations 
underscore the crucial role of bacteria-derived metabolites in the 
development of the immune system, locally and systemically.
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Bifidobacterium: milk oligosaccharides, fructose, bacterial 
polysaccharides, lactose (if malabsorption) 
Akkamansia: mucin and mucopolysaccharides 
FiGURe 2 | Overview of gut microbiota interactions in SCFA production and degradation. Figure depicts an overview of gut microbiota interactions in SCFA 
production and degradation, including substrates associated with bacterial utilization. Compared to Bacteroides spp., the Firmicutes phylum encompasses fewer 
genes for polysaccharide degradation, implying this phylum plays a vital role in nutrition metabolic pathways. Complex interactions also exist among intestinal fungi 
and dietary fibers (185). Compiled from Ref. (69, 164–168, 174, 175, 183, 185–206).
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Non-digested fibers and proteins, or amino acids (glycine, 
threonine, glutamate, lysine, ornithine, and aspartate) derived 
from microbial fermentation, can be precursors of SCFA in the 
colon (164–168). Exception may include branched chain amino 
acids (BCAAs), valine, leucine, and isoleucine (169). Anaerobic 
bacterial utilization can produce acetate, which can then be used 
by other bacteria to generate butyrate (168). Threonine can also 
be used for production of propionate (170, 171). In addition 
to the SCFA mentioned, lactate is important because bacterial 
groups compete for lactate and its utilization or production by 
certain bacteria may result in the production of hydrogen sulfide 
and other SCFA.
Gut Microbiota and Polysaccharide 
Utilization
Disease-related variability of the microbiome composition is 
important because the production of SCFA is highly dependent 
on microbial metabolism of host and dietary polysaccharides 
(“glycans”), their mucosal absorption, and local immunomodula-
tion. Figure 2 depicts an overview of gut microbiota interactions 
in SCFA production and degradation, including substrates asso-
ciated with bacterial utilization. Bacteroides possess collectively 
more hydrolase genes for utilization of polysaccharides of dietary 
and host origin (172–175). This is important in mucosal immu-
nology because germ-free (GF) murine colitis models colonized 
with specific commensal bacteria demonstrated localized bacte-
rial adaptation to host IgA-mediated responses via switching 
capsular polysaccharides, preventing opsonization and mucosal 
clearance (176). Bacteria can also adapt to chronic T cell-mediated 
inflammation by downregulating genes involved in their growth, 
while inducing growth of bacterial genes involved in metabolism 
of host-derived products of innate immunity, such as in NO 
(177). An example is Bacteroides thetaiotaomicron, implicated 
in the pathogenesis of human and murine models of IBD (178), 
which has genes for utilization of host-derived polysaccharides, 
when dietary sources are lacking during disease (179, 180). 
Patients with CD often have decreased levels of butyrate, and 
other SCFAs, consistent with the decreases in SCFA-producing 
Firmicutes as seen in taxonomic profiling studies (69, 181). In 
line with reduced SCFA production in IBD (181), metagenomic 
and metaproteomic studies also confirm decreased microbial 
gene expression for butanoate (butyrate) and propanoate (pro-
pionate) metabolism in patients with ileal CD (69), and that 
increased mucin (a polysaccharide-rich host mucosal secretion) 
degradation is inversely related to the abundance of Firmicutes in 
active CD (181, 182). To illustrate the complex dynamic interac-
tions in the gut mucosa, the beneficial properties of SCFA are 
TABLe 1 | Overview of fatty acid receptor ligands.a
HDACs FFAR1 FFAR2 FFAR3 FFAR4 GPR109A  
(HCAR2)
PPARy
Fatty acid 
ligands
Short-chain fatty 
acids; butyrate and 
propionate
Medium- and long-
chain saturated 
and unsaturated 
fatty acids, strongly 
activated by 
eicostrienoic acid 
(Natural: palmitic, oleic, 
pinoleic, ALA, DHA)
Highest affinity 
for acetate and 
propionate, 
also recognizes 
butyrate, caproate, 
and valerate
Short-chain fatty 
acids
Long-chain saturated 
and unsaturated fatty 
acids (natural: ALA, 
DHA, EPA)
Butyrate Long-chain 
unsaturated fatty 
acids
Proprionate, 
butyrate, acetate
Niacin (vitamin B3) Role for 
propionate in 
modulating 
expression
Lesser degree 
caproeate and 
valerate
Gene/
chromosome
HDAC gene family GPR40, human 
19q13.1 chromosome
GPR43, human 
19q13.1 
chromosome
GPR41, human 
19q13.1 
chromosome
GPR120, human 
10q23.33 
chromosome
NIACR1 human 
12q24.31 
chromosome
PPAR gene family
Expression Nucleus/cytoplasm 
of various cell types
HDAC proteins 
grouped into four 
classes (I–IV) based 
on function
Class I: HDAC 1, 
2, 3, 8
Class II: HDAC 4, 
5, 7, 9
Class IIB: HDAC 
6, 10
Class IV: HDAC 11
Pancreatic β-cells
Enteroendocrine cells
Osteoclastic cells
Intestine
Epithelial colonic 
cells
Immune cells 
(neutrophils, 
Tregs, eosinophils, 
macrophages, 
dendritic cells) 
Adipose tissue
Enteroendocrine 
cells
Pancreatic α and 
β-cells
Small intestine
Colon
Adipose tissue
Enteroendocrine 
cells
Sympathetic 
ganglions
Colon
Enteroendocrine cells
Adipose tissue, 
pancreatic cells, 
tongue (perception 
of fats)
FFAR4 (short)
Small intestine cells
Dendritic mesenteric 
FFAR4 (long)
Macrophages, 
neutrophils, T cells, 
glial cells 
Adipocytes
Keratinocytes
Macrophages
Neutrophils
Dendritic cells
Intestinal epithelial 
cells
Intestine
Macrophages
Adipose tissue
Physiological 
role
Class of enzymes 
involved in 
regulation of gene 
transcription/
expression
Insulin secretion in 
pancreatic cells
GLP-1 secretion
CCK secretion
Lipid and energy 
metabolism
Inflammatory 
processes in gut
Epithelial integrity
Neutrophil 
chemotaxis
Regulation of 
inflammatory 
processes in 
airways
Energy regulation 
via leptin 
production (may 
be mediated 
through FFAR2)
GLP-1 secretion in 
intestine. Macrophage 
activation M2 ≫ M1
Lipid sensor in 
adipose tissue
CCK secretion
Insulin sensitivity
Adiponectin 
secretion
Lipolysis inhibition
Immune cell 
activation
Apoptosis
Vasodilation
Master regulator 
adipogenesis
Insulin sensitivity
Lipogenesis
Adipocyte 
survival/function
Regulation of 
inflammation
Signaling 
pathways
Histone acetylation
NF-kB
CD4+ T cells
Fox3p
Calcium influx
Gαq/11
Gαi/0
β-arrestin-2
Calcium influx
ERK1/2 activation
Gαq/11
Gαi/0
Calcium influx
ERK1/2 
activation
Gαi/0
JNK, NF-kB
Calcium influx
ERK1/2 activation
FFAR4 (short)
β-arrestin-2
FFAR4 (long)
β-arrestin-2
Inhibition adenylate 
cyclase activity 
and reduced 
intracellular cAMP 
levels
Cholesterol 
transporter 
ABCG1
Pleiotropic 
effects by 
ligand-dependent 
transactivation of 
specific genes
Anti-inflammatory 
actions via NF-kB
aTable compiled from in-text references and (214–218).
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minimized when the colonic concentrations of H2S increases as 
byproduct of bacterial fermentation, which inhibits host DNA 
repair (183, 184).
Role of SCFA in Mucosal immunity
There are two major mechanisms of action by which SCFAs 
modulate host biological responses; namely, by direct inhibition 
of HDACs to directly regulate anti-inflammatory gene expres-
sion (207–210); and by acting as signaling molecules, activation 
of select GPCRs. As ligands, SCFAs bind with variable affinity 
to GPCRs, namely GPR43, GPR41 (renamed free fatty acid 
receptor 2 and 3; FFA2 and FFA3, respectively) (136, 211–213), 
and GPR109A (HCAR2; receptor for butyrate) (158, 211, 212) 
(Table 1).
Acetate, propionate, caproate (caproic acid; C6:0), and valer-
ate (valeric acid; C5:0) are all recognized by FFA2/GPR43, and 
while acetate and propionate are the strongest activators, FFA2/
GPR43 is the primary receptor for acetate (212, 219). FFA3/
GPR41 has arguably higher affinity for propionate than for 
acetate and butyrate (155, 211–213, 219, 220). Caproate and 
valerate are recognized by FFA3/GPR41, but to a lesser extent 
(221). FFA2/GPR43 and FFA3/GPR41 are expressed extensively 
throughout the small intestine and colon (211, 222, 223), but 
have also been detected in organs outside of the gut. FFA2/
GPR43 mRNA is present in adipose, skeletal, heart, and spleen 
tissues (211, 223, 224), being expressed on eosinophils, basophils 
(212), monocytes, neutrophils, DCs (212, 225), and mucosal 
mast cells (226).
TABLe 2 | Overview of fatty acids and features.
Fatty acid  
group
Definition Predominant fatty acid 
representativesb
Notes on nutritionc Notes on mucosal immunity
Short chain fatty 
acid (SCFA)a
<6 carbon 
atoms
No double C:C 
bonds
Formic (simplest carboxylic acid) acetic 
(C2:0), propionic (C3:0), butyric (C4:0) 
and Isobutyric, Valeric (C5:0) and 
Isovaleric
Butyric acid: various mixtures of 
dietary fibers, some types of resistant 
starch, fructo-oligosaccharides, 
beta-glucan. 
Acetic acid: mainly pectins.  
Proprionic acid: mainly guar gum
Regulation of colonic Treg pool. 
Modulation of Nf-KB via HDAC inhibition 
may facilitate the anti-inflammatory 
response by active suppression of pro-
inflammatory cytokine production
Medium-chain 
fatty acid (MCFA)
C6–C12
No double C:C 
bonds 
Caproic (C6:0), caprylic (C8:0), capric 
(C10:0), lauric (C12:0)
Coconut oil and palm kernel oil 
provide rich sources of straight chain 
MCFAs; lauric acid (C12:0), followed 
by caproic acid (C6:0), caprylic acid 
(C8:0), and capric acid (C10:0)
Lauric acid is a TLR agonist (TLR4), but 
also forms monolaurin in gut, a potent 
antimicrobial, antifungal
Long Chain Fatty 
acid (LCFA), 
Saturated
C14–C21
One or more 
double C:C 
bonds
Myristic (C14:0), palmitic (C16:0), 
palmitate (16:1), stearic (C18:0), stearate 
(C18:1), arachidic (C20:0).
Palmitic and stearic acid inherently 
part of vegetable oils. Coconut oil 
source of myristic acid
Depending on chemical structure, 
LCFAs impact membrane structure and 
fluidity and many are directly involved in 
intracellular signaling pathways, including 
receptor operated calcium channels
LCFA, 
Monounsaturated
C14–C21
One double 
C:C bond in 
position carbon 
9 (Δ9) 
Myristoleic (C14:1, cis-n-5;), palmitoleic 
(C16:1, cis-n-7), sapienic (C16:1, n-10), 
oleic (C18:1, cis-n-9), elaidic (C18:1, n-9), 
vaccenic (C18:1, cis-n-7), gondoic (C20:1, 
cis-n-9), erucic (C22:1, cis-n-9,), nervonic 
(C24:1, cis-n-9). Those not synthesized  
de novo include: gadoleic (C20:1, 
cis-n-11) and cetoleic (C22:1, cis-n-11)
Olive oil is one of the richest dietary 
sources, mainly due to oleic acid 
(78.4% ± 4.3), followed by canola, 
peanut (groundnut oil), avocado, 
hazelnut, and sweet almond oil. Rice 
bran, corn, and sesame oils in lower 
quantities
Lack of effect on eicosanoid biosynthesis. 
Modulate COX-2 expression
LCFA, 
Polyunsaturated
C14–C21
One or more 
double C:C 
bonds
Omega-3: ALA (18:3), EPA (20:5), DHA 
(22:6)
Omega-6: LA (18:2), CLA (cis-9, cis-12 
cis-18, cis-2) GLA (18:3), calendic acid 
(C18:3), Eicosadienoic acid (C20:2), 
dihomo-gamma-linoleic acid (DGLA, 20:3) 
and ARA (20:4)
ePA, DHA: murine fish oil or 
endogenous metabolic conversion 
via ALA. ALA: humans unable to 
synthesize, acquired only through 
dietary sources. LA: canola, corn, 
palm, soybean, sunflower, rice bran, 
and rapeseed oil. CLA: meat and 
dairy products.
EPA- and DHA-derive anti-inflammatory 
molecules protectins and resolvins
ARA-derived pro-inflammatory 
compounds, prostaglandins and 
leukotrienes involved in inflammation
n-3 LCFAs compete with the n-6 
precursors involved in eicosanoid 
synthesis and serve as substrates for 
potent lipid mediators
aMost SCFA are naturally saturated given the low number of carbons available for double C:C bonding saturation.
bIncomplete list of fatty acid isomers, but these are less understood, and present in the diet at a fraction of the lowest fatty acids listed.
cRefer to Figure 2 for overview of gut microbiota and SCFA production. Table comprised from in-text references and (245).
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SCFA-FFA2/GPR43 interactions profoundly affect inflamma-
tory responses. Marked amplifications of inflammation in the 
intestine and other organs are observed in FFA2/GPR43-deficient 
mice, while GF mice expressing little or no SCFAs exhibit similar 
dysregulation of inflammatory responses (227). SCFA-induced 
FFA3/GPR41 expression is a potent inducer of leptin in adipose 
tissue, but this may be mediated via FFA2/GPR43 (228). Leptin 
functions to regulate body weight, hunger, satiety and body tem-
perature, with increased expression in adipocytes in  vitro after 
treatment with acetate and propionate (228–230); propionate 
studies have shown adipose human mRNA leptin stimulation 
in  vivo (228). Interestingly, an overexpression of FFA2/GPR43 
was reported in mice fed a high-fat diet, but supplementation of 
inulin-type fructans (class of dietary fibers that resist digestion), 
counteracted these effects, including peroxisome proliferator-
activated receptor gamma (PPARy)-related adipogenesis (231). 
PPARy is a nuclear receptor involved in innate immune pathways, 
and PPARy deregulation has been associated with defective anti-
microbial response against Candida albicans, Bacteroides fragilis, 
Entercoccus faecalis, and E. coli (232). Recent evidence also 
implicated propionate in modulating PPARy expression (208).
Microbial fermentation of dietary fibers associated with 
butyrate, propionate, and acetate is summarized in Table  2. 
Overall, SCFAs help maintain epithelial integrity by promot-
ing mucus production (233, 234), by suppressing or altering 
pathways that produce various pro-inflammatory cytokines, 
chemokines (155) and adhesion molecules (235), or by interfer-
ing with inflammasome cytokines IL-8 and IL-22 (236). Butyrate 
appears to be the most potent with regard to host immunity in 
that it can actively suppress NF-kB formation (237, 238), repress 
production of TNFα, IL-6, and NO (162, 238, 239), and inhibit 
macrophage migration induced by bacterial LPS (240). Colonic 
epithelial cells also use butyrate as a main energy source (241, 
242) and have been shown to promote “physiological hypoxia” 
by increasing colonic epithelial cell oxygen consumption (243), 
which in turn, supports gut barrier function through hypoxia-
inducible factor (HIF) (244). Antibiotic therapy diminishes 
this effect, lowering both epithelial anaerobic metabolism and 
9Basson et al. Genetics, Diet, and Microbiome in IBD
Frontiers in Immunology | www.frontiersin.org August 2016 | Volume 7 | Article 290
luminal SCFA concentrations, resulting in HIF destabilization 
and barrier dysfunction (243).
LONG-CHAiN FATTY ACiDS
Monounsaturated Fatty Acids
Long-chain monounsaturated fatty acids (LCMUFAs; MUFAs) 
are largely represented by fatty acids formed by introducing 
a double bond in position carbon 9 (Δ9) counting from the 
carboxyl carbon. Major sources of long-chain monounsaturated 
fatty acids (e.g., olive oil) (245) are listed in Table 2.
In the clinical setting, olive oil-based n-9 lipid emulsions, 
administered parenterally, are considered an “immunoneutral” 
energy source and thus are used in combination with PUFAs 
for the therapeutic management of inflammatory illness (246). 
Epidemiologically, incorporation of MUFA-rich foods (e.g., olive 
oil), a cornerstone of the Mediterranean diet, is well-recognized 
for its beneficial effects on cardiovascular health (247), and 
because of its lack of effect on eicosanoid biosynthesis (248, 249), 
oleic acid is commonly used as the control fatty acid for PUFAs 
in dietary intervention trials. Notably however, several pieces of 
evidence demonstrate that olive oils (n-9) can modulate COX-2 
expression (250), thus providing a possible mechanism by which 
various dietary oils, rich in n-3 and n-6 PUFAs, or n-9 MUFAs 
influence chronic inflammation. Olive oil has been shown to exert 
inhibitory effects on COX-2 expression in IL-10−/− mice, thereby 
decreasing the risk of neoplasia associated with chronic colitis 
(251). One study demonstrated a close clustering of colonic gene 
and protein expression profiles between two mouse genotypes, 
IL-10−/− and C57BL/6J, fed either AIN-76A diet (LA-rich; corn 
oil) or an oleic acid-enriched modified AIN-76A diet (252). 
Comparing the top five pathways between the oleic acid and LA 
diet within the same mouse genotype revealed nine gene expres-
sion changes, representing six unique genes within IL-10 mice, 
and within the C57BL/6J oleic acid-fed mice, 32 unique genes 
increased in expression when compared to the LA-fed C57BL/6J 
mice. Proteomics revealed more colonic protein abundance 
changes within the IL-10−/− mice (16 proteins) than in C57BL/6J 
mice (7 proteins), with colonic protein changes (IL-10−/− or 
C57 mice) associated with a number of metabolic (e.g., energy, 
carbohydrate, and lipid metabolism) and signaling processes 
(e.g., immune, apoptotic, cytoskeletal), as well as pronounced 
increase in lipid metabolism protein levels, such as fatty acid 
binding proteins FABP4 and FABP6, and those related to cell 
structure assembly and signaling (252). The effects of n-9 oleic 
acid on host inflammatory responses, in some circumstances, 
may also be more indirect in nature. In one mouse model of 
Type 2 Diabetes (T2DM) pre-treatment with oleic acid reversed 
the inhibitory effects of TNFα on insulin production, while 
in  vivo, oleic acid-treated cells resulted in elevated transloca-
tion of the PPAR-activated receptor transcription factor to the 
nucleus (253).
Polyunsaturated Fatty Acids
Long-chain polyunsaturated fatty acids (LCPUFAs; PUFAs) 
are classified into omega-3 (n-3) and omega-6 (n-6) families 
(Table 2). The LCPUFA n-3 family includes alpha-linoleic acid 
(ALA; 18:3, n-3), and the most powerful LCPUFAs, eicosapen-
tanoic acid (EPA; 20:5, n-3), and docosahexanenoic acid (DHA; 
22:6, n-3), which can be directly acquired primarily in fish oils, 
or through endogenous metabolic conversion via ALA, their 
18-carbon precursor. However, humans are unable to synthesize 
ALA. EPA- and DHA-derived compounds can result in derived 
molecules referred to as protectins and resolvins, potent anti-
inflammatory mediators with distinct pathways of action (254–
257) and specific-binding receptors (e.g., ChemR23, leukotriene 
B4 receptor 1, GPR32, PPARy, GPR120) (258, 259). Both EPA 
and DHA can generate “resolution-phase interaction products” 
(resolvins) with the DHA-derived D-series resolvin, 17-HDHA 
(17-hydroxy-docosahexaenoic acid), and the EPA-derived 
E-series resolvin, 18-HEPE (18-hydroxy-eicosapentaenoic acid), 
characterized as the central pathway precursors and metabolites 
(260). Omega-6 LCPUFAs includes linoleic acid (LA; 18:2, n-6), 
gamma-linoleic acid (GLA; 18:3, a product of LA metabolism in 
the body), conjugated linoleic acid (CLA), and arachidonic acid 
(ARA; 20:4, n-6), as well as the ARA-derived pro-inflammatory 
eicosanoids, prostaglandins (PG; includes PTE2 and PGD2), 
and leukotrienes (LT; includes LTB4 and LTE4). Biological func-
tions of these eicosanoids include; vascular permeability and 
chemotactism in immune cells, transmigration of leukocytes and 
neutrophils into inflamed intestinal tissue involving adhesion 
molecules, and initiation of acute inflammation (261). Specifically, 
LTE4 upregulates COX-2 expression resulting in PGD2 genera-
tion in mast cells by a PPARy-dependent mechanism (262). Of 
note, increased levels of PGs with excessive production of other 
ARA-derived eicosanoids are observed in inflamed IBD mucosa, 
correlating with disease activity (263).
The effect of fatty acids in inflammation has been studied 
pre-clinically at various doses using primarily mouse models. 
Dextran Sulfate Sodium (DSS) colitis is a widely used murine 
model of IBD as it diminishes murine colonic regeneration elicit-
ing inflammatory cell infiltration into colonic mucosa. Among 
DSS models, the Fat 1 mouse model of endogenously increased 
n-3 PUFA, uniquely characterized by the de novo n-3 PUFA syn-
thesis from n-6 PUFA, has served to prove the anti-inflammatory 
effects of n-3 PUFAs (264–268). This model is important because 
of its ability to address molecular events underlying the effect of 
n-3 fatty acids in the absence of restricted dietary interventions, 
which may introduce potential confounding factors. There is 
however growing evidence that dietary n-3 PUFAs (DHA, EPA) 
also impair host immunity, increase B-cell function, and inher-
ently modulate humoral responses (269), although fatty acid 
composition and dosage govern these responses. For instance, 
lower dietary concentrations of n-3 LCPUFA (1% as; fish oil, EPA, 
DHA) are protective by inhibiting pro-inflammatory cytokines 
(270–272), whereas higher concentrations (6–8%) exacerbated 
DSS colitis (6, 251, 273). These LCPUFAs are competitive 
antagonists of lipoxygenase (LOX) and cyclooxygenase (COX), 
key enzymes in the biosynthesis of prostaglandins via ARA 
oxidation (260, 274, 275). n-3 LCPUFAs also compete with the 
n-6 precursors involved in the synthesis of eicosanoids (276, 277) 
and serve as substrates for potent lipid mediators and significant 
changes in the lipidome and eicosanome are seen in the presence 
of high fatty acid abundance (260, 274).
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Genetics Determine Binary inflammatory 
effect of Fat Diets and Microbiome
In addition to fatty acid composition and dosage, host genetics 
(genomic background or single gene mutations) contribute to 
LCPUFA-mediated mechanisms. Comparing two mouse mod-
els of disease may illustrate such clinical dichotomy. Compared 
to a n-6 unsaturated and a saturated fat diet, a diet rich in n-3 
PUFA (8% fish oil, EPA, DHA), which worsens DSS colitis 
(two 7-day cycles) in C57BL/6 mice, ameliorates the disease 
and decreased MAdCAM-1 expression in a mouse model of 
CD-like ileitis (SAMP1/YitFc, SAMP1) (278). With respect 
to PPARy signaling, SAMP1 mice exhibit complex-, age-, and 
tissue-specific regulation (79), with PPARy staining extending 
only from the base to the tip of intestinal villi, remaining absent 
in the epithelial crypts, independent of age (79). In SAMP1, 
treatment with PPARy agonist roglitazone has no beneficial 
effects on the severity of ileitis (79). However, feeding n-3 to 
C57BL/6 mice decreased adiponectin and colitis severity, but 
the effect was canceled by pioglitazone, a PPARy agonist, sug-
gesting the mechanism involves PPARy (278). Perhaps one of 
the most important studies demonstrating how host genetics 
interacts with diet, obesity traits, global gene expression, and gut 
microbiota composition in response to a high-fat/high-sucrose 
diet tested >100 inbred mouse strains (279) and revealed that 
high-fat/high-sucrose feeding promoted a wide, strain-specific 
variation in the gut microbiome, depending on mouse strain, 
and identified an association between a region of chromosome 
3 (contains three amylase genes), with a significant enrich-
ment of Enterobacteriaceae on the high-fat/high-sucrose diet. 
Previously, a study of 65 species-level phylotypes correlating 
differences between the gut microbiome and diet revealed that 
genetics and diet account for 12 and 57% of total microbiome 
variation (280). The authors also noted an increase in sulfate-
reducing Desulfovibrionaceae in animals with impaired glucose 
tolerance.
Human studies support interactions between genetic back-
ground/ancestry, dietary LCPUFA intake, plasma/tissue fatty 
acids, and microbiome (260, 281–286). For instance, monozy-
gotic (identical) twins have more similar microbiomes that 
dizygotic twins or unrelated individuals (98, 287–290). The 
role of host diet–gene interactions is also modulated by epi-
genetic effects; hypothetical effects have been proposed for 
n-3 LCPUFAs on cell proliferation, survival, and immunity 
(291–293). Maternal exposure to LCPUFA is known to alter the 
gut microbiota in offspring; n-3 fish oil increases Bacteroidetes; 
other fish oil diets increase pathobionts linked to altered 
immunity, namely B. wadsworthia, Enterococcus faecium, and 
B. fragilis, and n-6 safflower oil increases Firmicutes (294–296). 
PUFA (i.e., n-6) exposure can also induce epigenetic protective 
effects (transferrable to GF mice via FMT) in young animals 
against DSS colitis (297).
PUFA and Microbial inhibition
While some studies support in  vitro and in  vivo antibacterial 
effects of LCPUFAs (e.g., liposomal LA formulations against H. 
pylori), others indicate adverse effects (298–305). Of interest, 
bacterially produced LCPUFAs may also exert anti-microbial 
effects, for instance, Bifidobacteria can produce C18:3 and 18:4 
conjugated fatty acids effective in inhibiting gastrointestinal 
pathogens, including methicillin-resistant S. aureus (306). 
Yeasts, fungi, microalgae, and Thraustochytrids can also produce 
LCPUFAs, implying that microbiota structure influences fatty 
acid composition in the gut, and systemically if absorbed (5, 307). 
The anti-inflammatory, immunomodulatory effects of n-3 fatty 
acids on host inflammation that attenuate tissue damage, inflam-
mation, and improve survival against Gram-negative bacteria, 
may equally function to reduce the generation of cell-mediated 
immunity, diminishing host resistance to gram-positive intracel-
lular pathogens.
Overall, the bacterial response a LCPUFA induces (i.e., 
bacterial survival, dysbiosis) (251, 270, 273, 308–310), depends 
on the type of infectious agent (6, 260), diversity and richness 
of gut microbiota (311), and the n-3:n-6 dietary LCPUFA ratio 
(312, 313). In C57BL/6J mice fed with high-fat diets for 5 weeks 
(high corn oil, n-6 PUFA; corn oil +  fish oil; supplemented 
n-3 PUFA; and low fat control, n-6 PUFA; 5% corn oil) and 
infected with Citrobacter rodentium to induce colitis, both 
high-fat diets reduced Bacteroides spp. and increased Clostridia 
spp., with a concomitant reduction in Clostridium coccides 
in the fish oil-supplemented mice (309). Supplementation 
with n-3 PUFA reversed the n-6 PUFA-induced dysbiosis by 
reducing Enterobacteria and Segmented Filamentous Bacteria, 
while increasing Lactobacillus spp., Bifidobacteria spp., and E. 
faecium. Clinically, mice in n-3 PUFA had higher sepsis and 
mortality [higher serum LPS-binding protein, TNFα and IL-5, 
and reduced intestinal alkaline phosphatase (AP)] (309), while 
n-6 PUFA exhibited lower disease severity. With transcriptom-
ics, EPA and ARA (arachidonic) enriched AIN-76A diets (fat 
free +  1% corn oil +  either 3.7% ARA, EPA, or oleic acid) 
modulates the colonic gene expression patterns following 
inoculation of mice with either complex intestinal microflora or 
pure bacterial cultures (E. faecalis and E. faecium, in C57BL/6J 
IL-10−/− mice) (314).
Another example of interactions between fatty acids and flora 
are CLA, which are characterized by the presence of conjugated 
double bonds with cis or trans configuration representing posi-
tional and geometric isomers of LA (cis-9, cis-12, cis-18, and cis-
2). In humans, the primary source is dairy and ruminant meat. In 
ruminants, the source of CLA is endogenous bio-hydrogenation 
of LA, via fatty acid intermediates; stearic acid (18:0 CLA 
isomers), and vacceinic acid (trans-11-C18:1, which can be 
desaturated into rumenic acid; cis-9, trans-11-C18:2) (315–320). 
Similar pathways exist for the gut microbiota, with some 
endogenously producing CLA (321–323). Diets enriched with 
CLA may promote Bacteroidetes/Prevotella and Akkermansia 
muciniphila in C57BL/6J mice (324). The three major bacterial 
genera Bifidobacteria spp. (325, 326), Lactobacillus spp. (327), 
and Roseburia spp. (322), can produce CLA and vaccenic acid, 
and co-administration of LA with Bifidobacterium breve was 
shown to increase fatty acid tissue composition of rumenic acid 
(cis-9, trans-11–18:2 CLA) in mice (328). Thus, CLA acts as a 
metabolite precursor for specific microbes, which may modulate 
gut barrier function. Together, this section highlights that host 
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responses to a microbial agent are highly dependent on the 
dietary fat intake.
MeDiUM-CHAiN FATTY ACiDS
Medium-chain fatty acids (MCFA) are fatty acids found in 
medium-chain triglycerides (MCTs), saturated fats comprised of 
a glycerol and three fatty acid chains, two or three of which are 
6–12 carbon atoms in length. MCTs are primarily gathered into 
straight chain (unbranched) fatty acids, but side chain (branched) 
fatty acids (e.g., nonanoic acid) also exist. Sources of MCFAs 
are listed in Table  2. Of note, lauric acid (C12:0) is the main 
antibacterial and antiviral substance found in breastmilk and 
in the gut is enzymatically broken down to form monolaurin, 
a monoester with profound anti-microbial and anti-fungal 
properties against lipid-coated bacteria, including inactivation 
of H. pylori and Listeria monocytogenes (329).
Evidence indicates that MCFAs, mainly lauric acid (C12:0), 
act as “non-microbial” agonists to TLR4 triggering inflammation 
pathways similar to gram-negative-derived LPS (330–333). High-
fat SFA intake modifies gut microbiota with an overproduction of 
LPS and endotoxemia enhancing TLR4 activation (333, 334). The 
oxidative stress caused by this dietary metabolic endotoxemia 
produces oxidative molecules, which activate inflammation via 
CD36–TLR4–TLR6 and CD14–TLR4–MD2 (334–337), with 
MyD88-dependent and independent pathways (338) promoting 
expression of transcription factor NF-kB and pro-inflammatory 
COX-2, TNFα, IL-1β, IL-6, IL-8, IL-12, INFy, MIP1-α/β/2, 
MCP1, VCAM1, and RANTES (330, 335, 339–342).
In IL-10−/− mice, a subset of colonic mononuclear phago-
cytes that express MyD88 and signal through TLR ligands are 
the initiators of colitis (343), and studies demonstrated that 
partial replacement of dietary LCPUFAs with MCTs (lauric 
acid: 28 g/100 g total fat) decreased the severity of colitis, CD3+ 
intraepithelial lymphocytes (by increasing apoptosis), and pro-
inflammatory cytokines IL-6 and INFy, in IL-10−/− mice (344). 
Under specific pathogen-free conditions for mRNA assessment 
of TLR-2 and TLR-9, gram-positive sensors of commensal intes-
tinal bacteria occur solely through a MyD88 pathway, instead of 
TLR4 (i.e., gram-negative bacteria) (344). Assessment of TLR-2 
and TLR-9 gene expression as sensors of gram-positive bacteria 
via MyD88 showed that the MCT diet decreased TLR-9 while 
TLR-2 was unaltered (344).
One MCT (i.e., MCFA) formulation, largely comprised of 
caprylic acid (97.8%, C8:0), has been shown to reduce intestinal 
inflammation and exert stronger anti-inflammatory effects than 
LCTs (i.e., LCFA) in a trinitrobenzene sulfonic acid (TNB)-
induced ileitis in rats (345, 346). Intraileal injection of TNBS 
with the MCT formulation tended to reduce the levels of mucosal 
TNFα and LTB4, with levels 72% of the corresponding value 
in the LCT group (74.2% linoleic, C18:2; 14.8% oleic, C18:1) 
(345, 346). Using the same model, it was shown that gavaging as 
little as 1.5 ml of the MCT formulation can mediate polymopho-
nuclear activation and mucosal infiltration, including that the 
LCT formulation (1.5  ml) promoted greater proinflammatory 
activity (345, 346).
SPHiNGOLiPiDS
Sphingolipids, present in small amounts in most foods, are a class 
of lipids containing a backbone of 18 carbon amino-alcohols that 
includes sphingosine, and are synthesized in the endoplasmic 
reticulum from non-sphingolipid precursors (347). In a Western 
diet, complex sphingolipids (sphingomyelin, cerebrosides, 
gangliosides, glycosphingolipids) can reach 0.3–0.4  g per day, 
with dairy, eggs, meat, and soy being rich sources, followed by 
cereals, vegetables, pulses, and fruits (348, 349). Animal products 
contain all complex sphingolipids, whereas plants contain mostly 
cerebrosides and structurally diverse glycosyol inositol phospho-
ceramides (347).
Intestinal sphingolipid digestion is catalyzed by the three iso-
forms of sphingomyelinase (SMase) and ceramidase (CDase), 
each compartmentalized in the gut depending on local and 
mucosal pH (acidic, A-SMase and A-CDase; neutral, N-SMase 
and N-CDase; alkaline, Alk-SMase and Alk-CDase), with 
A-SMase mainly localized in highly proliferating crypt cells, 
especially in small intestine, and Alk-SMase primarily in the 
brush border of the mid-intestine. N-CDase (acidic) exhibits 
the highest activity in the presence of bile salts, but direct 
sphingomyelin and cerebroside absorption cannot be excluded 
(350). In the gut, complex sphingolipids are part of intestinal 
membranes, which play an important role in regulating diges-
tion, absorption, and protecting the mucosa (351, 352). Selective 
abundance of sphingomyelin and glycosylceramide (GlcCer) is 
characteristic to enterocytes in the human small intestine, with 
high levels associated with selective enrichment and localiza-
tion of several microbial species in the apical membrane of 
villous cells, paralleling the constant differentiation of mucosal 
cell throughout the crypt-villus axis (352, 353). Abnormal 
sphingolipid metabolism and composition patterns have been 
linked to inflammatory responses, as well as abnormal intestinal 
permeability during IBD via abnormal intracellular tight junc-
tions (351).
Intestinal metabolism, dietary catabolism and “de novo” 
synthesis, involves multiple enzymes, signaling pathways, and 
metabolites such as ceramide, sphingosine, and derivatives 
ceramide-1-phosphate (C1P) and sphingosine-1phosphate 
(S1P) (351, 354). Increases in ceramide, sphingomyelin and 
their 1-phosphorylated derivatives C1 and S1P with decreased 
GlcCer is believed to contribute to IBD progression (347, 352, 
354, 355). These metabolites modulate eicosanoid production 
important in inflammation by exerting synergistic effects (of 
C1P and S1P) in the activation of cPLA2-α and COX-2, with 
C1P and S1P involved in PGE2 production (356–362). Simple 
sphingolipid intermediates (sphingolipids/sphingoids) medi-
ate cell survival, proliferation, differentiation and apoptosis, 
whereas the dietary metabolite of sphingomyelin, ceramide, 
mediates intestinal epithelial cell apoptosis by capthesis D 
activation, which impairs absorptive and mucosal barrier (363). 
At the cell-to-cell adhesion level, sphyngolipids can modulate 
tight junctions; dietary gangliosides induce claudin-1 expres-
sion, whereas GlcCer inhibits occludin degradation (364, 365). 
Together, the sphyngolipid metabolism can be modified by diets 
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rich in fibers (psyllium) and fats (366), tetrahydroxyfavone 
and luteolin (367, 368) (fruits, vegetables, medicinal herbs), 
and probiotic bacteria (VSL#3) (369), which regulates mucosal 
inflammation (351).
BiLe ACiDS
Bile acids are steroids predominantly found in the bile of mam-
mals and conjugated with taurine or glycine by the cytochrome 
P450 enzyme, cholesterol 7α-hydroxylase (CYP7A1) in the 
liver to form bile salts. Primary bile acids, cholic acid (CA) 
and chenodeoxycholic acids (CDCA)/ursodeoxycholic acid 
(UDCA), are those synthesized in the liver while second-
ary bile acids, deoxycholic acid (DCA) and lithocholic acid 
(LCA), result from bacterial 7α/β–dihydroxylation in the colon, 
primarily via the genus Clostridium, including C. scindens, C. 
hiranonis, C. hylemonae (Clostridium cluster XVIa), and C. 
sordelli (Clostridium cluster XI) (370). Bile acids differentially 
activate the nuclear receptors, farsenoid X receptor (FXR), 
pregane X receptor (PXR), and the vitamin D receptor (VDR), 
the latter a feedback mechanism that represses bile acid synthe-
sis (371, 372). Specific bile acids also serve as natural ligands for 
TGR5, a GPCR highly expressed in gallbladder epithelial cells, 
shown to influence bile acids, intestinal motility, the immune 
system, and energy and glucose homeostasis by increasing 
GLP-1 production (371, 373, 374).
In humans, bile acid pool size and composition are impor-
tant elements in regulating microbial community structure, 
and low levels have been significantly correlated with gram-
negative bacterial dysbiosis, including potent producers of LPS 
(375), while favoring reductions in microbial species involved 
in secondary bile acid formation (e.g., Clostridium genus) 
(375–378). Bile acid feeding (CA) in rats resulted in significant 
inhibition of Bacteroidetes and Actinobacteria, with significant 
phylum-level expansion of Firmicutes, including members of 
Clostridium Cluster XIVa closely related to DCA-producing 
7α-dehydroxylating species (379, 380). In one diet-related model 
of colitis, mice fed a AIN-93G diet supplemented with 0.2% 
deoxycholate (8 months), colonic inflammation and histological 
changes correlated (over time) with the increases or reductions 
in gene expression central to epithelial barrier function, inflam-
mation, oxidative stress, cell proliferation/cell cycle/DNA repair, 
and related processes (381).
Bile holds clear antimicrobial activity, both indirectly, through 
FXR-induced antimicrobial peptides, and directly, through 
bacteriostatic functions on intestinal microbes, although some 
bile-tolerant microbes not only exist, but thrive in the pres-
ence of bile acids (382–384). Devkota et  al. produced the first 
paper demonstrating that a Western-based diet containing high 
amounts of a particular saturated fat source (milk fat), enhanced 
development of colitis in IL-10−/− mice via a specific molecule, 
taurocholic acid (382), correlating with a significant bloom in 
Bilophila wadsworthia, a sulfite-reducing bacterim and member of 
Deltaproteobacteria. This bile acid-resistant bacterium expresses 
enzymes, such as bile salt hydrolase (BSH), which facilitates bile 
salt deconjugation (385, 386). Other BSH-expressing-microbiota 
includes some pathobionts (e.g., E.coli and L. monocytogenes), 
members of the gut commensals (e.g.,  Lactobacillus and 
Bifdobacterium spp.), and members of the  Bacteroides genus, 
such as B. fragilis (383, 385, 386), although the latter yields 
BSH shown to “attack” the taurine conjugates of dihydroxy bile 
acids more readily than trihydroxy taurine conjugates (385). 
One study demonstrated that the antioxidant, tempol targets 
BSH-producing Lactobacilli, inducing a near inversion of the 
Firmicutes to Bacteroides ratio (387). In a follow-up set of stud-
ies by Devkota and colleagues, a milk-fat diet supplemented with 
5% n-3 fish oil completely inhibited blooms of B.wadsworthia, 
seemingly mediated shifts in bile acid composition (388).
These findings hold important clinical implications for 
patients with IBD considering several studies report increased 
sulfate-reducing bacteria (e.g., Desulfovibrio) in fecal and 
mucosal biopsies (389–392), and metagenomics observations of 
increased functionality characteristic of auxotrophic and patho-
biont bacteria, namely decreased biosynthesis of amino acids, and 
increased sulfate transport (particularly in ileal CD), correlating 
with increased expression of the amino acid transporter genes 
involved in metabolism of cysteine, a sulfur-containing amino 
acid (183, 186). These organisms have a reduced ability to pro-
duce their own nutrients, but rather transport them from sites 
of inflammation and tissue destruction where they are readily 
available. Nitrate-derived products generated from the inflamed 
gut can be utilized by Enterobacteriaceae, particularly E.coli, to 
out-compete commensals which require fermentation substrates 
(184). Mesalamine treatment has been associated with decreases 
in Escherichia (69), and found to inhibit fecal sulfide production 
in UC patients (393).
Alkaline Phosphatases
In addition to bile acids favoring the absorption of dietary fats, AP, 
are important enzymes produced by most host cells (especially 
epithelial cells) that assist in the absorption and transport of fatty 
acids. APs are encoded by a large family of genes ubiquitously 
expressed in multiple tissues. Mice AP isozymes are encoded by 
five loci, one of which, the Akp3, encodes for the duodenal-specific 
IAP isozome (dIAP) (394). Human AP isozymes are encoded by 
four different genes, three of which are tissue-specific alkaline 
phosphatase (TSAP) (i.e., expression restricted to intestine, pla-
centa, germ cells), while the fourth, tissue non-specific alkaline 
phosphatase (TNAP), is expressed in bone, kidney, liver, and 
other tissues. In human hepatocytes, bile acids increase TNAP 
activity (395), and its secretion in bile (396), suggesting TNAP 
exerts inhibitory effects on bile secretion (394, 397). The liver is 
the major LPS-removing organ, and one important function of 
TNAP is to dephosphorylate endotoxins, such as LPS (398, 399). 
By contrast, murine TNAP, encoded by Akp2, is not expressed by 
mouse hepatocytes (400).
Intestinal alkaline phosphatase (IAP) is involved in fatty acid 
absorption and in a rate-limiting step of fatty acid transport in the 
gut, modulated via Akp6 IAP isozyme (global IAP or gIAP) and 
FAT/CD36 expression levels, a phosphorylated fatty acid trans-
locase facilitating the transport of LCFAs into cells (401–404). 
As a brush border enzyme, IAP protects gut barrier function and 
the detoxification of bacterial LPS, through dephosphorylation 
(405). Compared to WT mice, Akp3−/− mice (i.e., dIAP-deficient) 
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exhibited considerably different and fewer types of aerobic and 
anaerobic microbes in their stools, whereas IAP supplementation 
restored growth of commensal bacteria, but inhibited growth of 
Salmonella typhimurium (406). Interestingly, oral administration 
of IAP had a protective effect against DSS-induced colitis (four 
cycles of 2% DSS ad libitum for 7 days) in Akp3−/− mice, attenuat-
ing disease in both Akp3−/− mice and WT mice (407).
DieTARY AMiNO ACiDS
Tryptophan
Dietary tryptophan is an essential amino acid found in fish 
and cruciferous vegetables (broccoli, cauliflower, and cabbage) 
that can activate the AhR, mostly through the formation and 
metabolism of tryptophan-derived metabolites. The AhR is a 
basic helix-loop-helix/Per-Arnt-Sim (bHLH-PAS) transcription 
factor containing several modular domains: N-terminal bHLH 
domain (DNA binding); two PAS domains (PAS A and PAS B) 
required for ARNT dimerization; and a transactivation domain 
of the C-terminus consisting of acidic, glutamine Q-rich and pro-
line/serine/threonine (P/S/T)-rich regions, responsible for gene 
transcription, and protein–protein interactions with co-regulator 
proteins (408, 409). Expressed by epithelial, immune and some 
tumor cells, the AhR modulates host immunity, and protects 
against extracellular pathogens at epithelial sites by promoting 
functional differentiation of interleukin-17-producing Th17 cells 
of the lamina propria (410–414). AhR activation is also required 
for IL-22 production (Th17 cells) (415–417) and promotes IL-22 
expression in group 3 innate lymphoid cells (ILC3) (418). IL-22 
secretion stimulates production of antimicrobial peptides (Reg3β 
and Reg3y) (419, 420) and mucus (421, 422), crucial factors in 
maintaining epithelial integrity.
The first tryptophan-derived AhR mechanism involves the 
catabolism of tryptophan by the rate-limiting enzyme indoleamine 
2,3-dioxygenase in the kynurenine pathway, thereby producing 
l-kinurenine, an AhR ligand (423, 424) associated with promot-
ing Tregs (425) and DCs (426). Indoleamine 2,3-dioxygenase 
produced by alternatively activated macrophages (427) inhibits 
intracellular pathogens such as Toxoplasma and Chlamydia via 
INFy, and has anti-proliferative effects on tumor cells (428, 429), 
although depletion of l-tryptophan attenuates these effects (430). 
Rosmarinic acid, a caffeic acid ester found in various plants, can 
inhibit indoleamine 2,3-dioxygenase expression because of its 
COX-inhibiting properties (431). COX-2 inhibitors have a similar 
effect in that they downregulate indoleamine 2,3-dioxygenase 
production, leading to reduced kynurenine levels (432, 433). 
Of interest, tryptophan-derived kynurenic acid also acts as a 
signaling molecule for certain GPCRs (434, 435), and the protein 
structural motif of AhR is comparable to HIF/HIF-1α recep-
tors (bHLH-PAS family) (436), thus illustrating the important 
relationship between environmental signals and host cellular 
responses (437, 438).
The second tryptophan-derived mechanism occurs through 
tryptophan metabolism as an energy source by Lactobacilli 
(L. reuteri, L. johnsonii), to produce indole-3-aldeyde, an AhR 
activator that induces IL-22 transcription (439). These interac-
tions generate microbiota resistance to C. albicans colonization 
and are protective against mucosal inflammation (439). AhR-
deficient mice exhibit shifts in microbial composition (increased 
Bacteroidetes), marked by increased epithelial permeability and 
colitis severity, whereas diets enriched in AhR ligands partially 
reversed these effects (416). Another dietary-derived AhR ligand, 
indole-3-carbinol (I3C), a component of the same cruciferous 
vegetables as tryptophan, also alters gut microbiota composition 
(416, 422, 440), implying that AhR ligands, including the recep-
tor itself, mediates microbiota profiles. Finally, the tryptophan-
derived lipophilic molecule, 6-formylindolo(3,2-b) carbazole 
(FIZC), a high-affinity AhR ligand, elicits increased activation 
of natural killer cells, increased INFy production and cytolitic 
activity (441, 442).
The AhR recognizes tryptophan and many other ligands 
derived from food antigens, phytochemicals [flavonoids (443)], 
polyphenols (444) [quercetin (445, 446), curcumin (447), res-
veratrol; all AhR antagonists (444)], ARA products (PGs and 
lipoxins A4), and natural chemicals, including those derived from 
dietary bacterial metabolites (19). For example, Propionibacterium 
freudenreichi, a bacterium from Swiss-type cheese, produces 
vitamin K2 precursor, 1,4-dihydroxy-2-naphtholic acid, to 
activate AhR in vivo, increasing antimicrobial peptide synthesis 
in mice (448). Other bacterial AhR ligands control antibacterial 
responses against Mycobacterium tuberculosis and Pseudomonsa 
aeruginosa (449). Numerous in  vitro and in  vitro studies have 
shown an interaction between AhR and retinoic acid signaling 
pathways (i.e., RXR), including AhR binding to some synthetic 
retinoids (450). Environmental pollutants, particularly 2, 3, 7 ,8 
tetrachlorodibenxo-para-dioxin (TCDD) (Dioxins), and polycy-
clic aromatic hydrocarbons (PAHs), such as those from tobacco 
smoke, are also AhR activators (451), although AhR binding by 
a xenobiotic- or a dioxin-response element (XRE/DRE) in the 
promotor region of genes requires activation by a ligand (452, 
453). Notably, AhR pathway activation through exposure to 
environmental compounds alters the synthesis, catabolism, 
transport, and excretion of retinoic acid. The AhR-mediated 
effect on retinoid homeostasis may upregulate or downregulate 
gene expression (450), and can be enhanced by VDR presence, 
given its interaction with other receptors (e.g., RARs, RXRs) (19).
Aryl hydrocarbon receptor signaling pathways are sensitive 
to oxidative stress. Crosstalk between other pathways can indi-
rectly activate AhR signaling, inhibiting the metabolic turnover 
endogenous AhR ligands. This interaction can mediate mucosal 
oxidative stress by regulating cytochrome P450 monooxygenase 
1 protein enzymes (CYP1s) involved in drug metabolism, with its 
antagonistic effects on the estrogen receptor extensively described 
(409, 452, 453). In addition, the AhR works in close concert with 
the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) (454–456), 
a master regulator of antioxidant responses that protects cells 
against reactive oxygen species (ROS) by inducing expression of 
many cytoprotective molecules (e.g., enzymes) (457). Oxidative 
stress by Nrf2 interacts with the AhR pathway. For example, the 
AhR ligand TCDD directly upregulates Nrf2 and phase II liver 
metabolizing enzymes via the multiple copies of XRE/DRE 
in promotor regions of human Nrf2 genes (458). AhR/ARNT/
Nrf2 can also engage in the mutual binding of XRE/DREs (458). 
Intriguingly, TCDD-induced AhR activation impairs Th2-type 
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immunity (459–465), whereas TCDD activation of Nrf2 overall 
promotes CD4+ T cells toward Th2 differentiation, induces Th2-
derived cytokines IL-4, IL-5, and IL-13, subsequently suppressing 
INF-y production (466–471).
Signals or stresses generated from host microbiota also have 
the potential to activate Nrf2 cross-talk with AhR pathways, 
influencing metabolic processes. Increased oxidative stress has 
been described in high-fat, diet-induced obesity (472); however 
Nrf2 KO mice fed a high-fat diet (3 and 6 months), gain signifi-
cantly less weight over time, have higher insulin sensitivity and 
more glucose tolerance compared to WT mice (472, 473). The 
exact role of Nrf2 in adipogenic pathways remains controver-
sial; some reports indicate Nrf2 deletion impairs adipogenesis 
through PPARy (472), whereas others indicate Nrf2-induced 
activation of AhR can inhibits adipogenesis (474). These dis-
crepancies may be attributed to differences in cellular models 
or glutathione potential (i.e., ROS levels) as a result of Nrf2 
expression levels (455).
Glutamine
Glutamine is another important amino acid that mediates 
mucosal metabolism, and Nrf2 target genes are involved in glu-
tathione synthesis (475). The Nrf2 pathway impacts glutamine 
and glutamate metabolism, although glutamine concentrations 
may not necessarily define cellular glutamate levels (476, 477). 
Glutamine is one of the most abundant non-essential amino 
acids in the body, serving as a source of nitrogen in the citric acid 
cycle and many anabolic processes (478, 479). Its importance 
in the immune system lies in the support of different pathways, 
such as cytokine secretion and T cell proliferation, and that 
immune cells transform glutamine to glutamate in high rates 
(480). Obese rats fed glutamine have decreased TNFα and IL-6 
in serum and peripheral tissues (481, 482), but little is known on 
the effects of l-glutamine on gut microbiota. In humans, a study 
of overweight and obese volunteers (BMI ≥25  kg/m2) showed 
that l-glutamine (30  g) supplementation Veillonella genera is 
positively correlated with higher levels of epithelial inflamma-
tion and the occurrence of and colitis (120, 483). Glutamine 
supplementation decreased the Firmicutes to Bacteroidetes ratio 
(from 0.85 to 0.57) and reduced Actinobacteria, compared to 
l-alanine supplemen tation (484).
HYDROSOLUBLe viTAMiNS
B Complex
The vitamin B complex includes niacin (B3), riboflavin (B2), 
cobalamin (B12), biotin (B8), folate (B9), thiamin (B1), pan-
tothenate (B5), and pyridoxine (B7) (485). The main source of 
Vitamins B for animals and humans is the gut microbiota, but 
the gut microbial gene profiles present in all hosts is highly 
variable, and some microorganisms lack essential biosynthetic 
genes. To compensate for such deficiencies microbes exchange 
B-vitamin molecules with other microbes (486). In short, 
vitamin B-deficient genomes are grouped in three types. 
Most gut Actinobacteria can produce only niacin, pyridoxine, 
and thiamin; Some Firmicutes and Actinobacteria lack all 
genetic pathways, except for niacin; and some Firmicutes and 
Proteobacteria lack all pathways except those for biotin and 
folate (486).
Niacin
Niacin (vitamin B3) is directly involved in GPR109A activation 
(known as Niacin1 receptor), because aside from butyric acid 
(C4:0) (158), the receptor also interacts with the metabolite 
nicotinic acid, an end product of tryptophan degradation (487). 
Activation of GPR109A by nicotinic acid induces Treg develop-
ment and expression of anti-inflammatory molecules within 
macrophages and DCs (158). Complementary relationships in 
the synthesis pathways between microbiota have been described 
(486). For instance, cobalamin (vitamin B12) synthesis pathways, 
which are missing in several Bacteroidetes and Proteobacteria, 
are present in other Firmicutes, whereas those Firmicutes lacked 
pathways held by the respective Bacteroidetes and Proteobacteria. 
Among the Firmicutes, some members of the Clostridia class 
are cobalamin producers, whereas all Lactobacillales are non-
producers, with the exception of some L. reuteri and Bacillus 
strain (L. monocytogenes 1/2a F6854) (486). Interestingly, three 
non-redundant vitamin B12 receptors are expressed by B. the-
taiotaomicron, giving it competitive advantage for certain B12 
analogs (488).
Riboflavin
Riboflavin production by the human gut microbiota has been 
associated with activation of T cells, and riboflavin precur-
sors selectively activate mucosal-associated invariant T cells 
(MAIT) by their presentation via the major histocompatibility 
complex (MHC)-related protein MR1 (489, 490). Riboflavin is 
also used as a major redox mediator for extracellular transfer 
by the butyrate-producing and main acetate-consuming bac-
terium F. prausnitzzi, and in vitro, flavins (such as riboflavin), 
in combination with cysteine, are a prerequisites for promot-
ing the growth of this strictly anaerobic bacterium, however 
glutathione, a primary thiol-containing antioxidant in the 
gut, was found to facilitate this process (491, 492). Riboflavin 
synthesis has been reported to be enabled in the genomes 
of half Firmicutes and most Bacteroidetes, Fusobacteria, 
and Proteobacteria tested. Conversely, most Actinobacteria 
cannot produce it, but compensating have (RibU) riboflavin 
transporters to utilize available preformed riboflavin, as do the 
non-producing Firmicutes (486).
Increased glutathione transport and riboflavin metabolism 
is observed in patients with UC (69), whereas marked reduc-
tions in F. prausnitzii, with concomitant increases in E.coli 
abundance is observed in patients with ileal CD (59, 68). In 
healthy volunteers, oral riboflavin supplementation (100  mg) 
preferentially increased F. prausnitzzi and Roseburia, and 
reduced Enterobacteriaceae (E. coli and relatives) abundance 
(493). Following the cessation of riboflavin supplementation, F. 
prausnitzzi numbers dropped significantly in all volunteers. Of 
interest, the essential roles for folate metabolism are missing in all 
studied F. prausnitzii genomes, and while growth of F. prausnitzii 
A2-165 has not been found require folic acid (494), it has been 
suggested that folate may enhance growth of this bacterium. 
Taken together, perturbations to the gut microbiome may impact 
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individual B-vitamin requirements, and deficiencies in one or 
more B-vitamins, may impact the gut microbiome leading to 
proliferation of inflammation-promoting organisms (486). The 
therapeutic use of B-vitamins could serve as a novel strategy to 
modulate microbial physiology.
Choline
Choline can be synthesized in small amounts by the liver, and 
is an important member of the B-vitamin-complex (495, 496). 
Phosphatidylcholine is a type of phospholipid in lecithin, and 
structurally, phosphatidylcholine is comprised of a SFA, an 
unsaturated fatty acid, a glycerol, and a quaternary ammonium 
compound that comprises a choline group. Carnitine itself is 
a quaternary ammonium compound biosynthesized from the 
amino acids lysine and methionine, and the choline group within 
carnitine is structurally similar to that found in phosphatidylcho-
line (496). Dietary sources of phosphatidylcholine and carnitine 
include animal-based foods such as red meat, eggs (yolk), milk 
and certain fish, which provide significant sources of choline in 
the body. In a metabolomics-based dietary intervention study, 
foods rich in phosphatidylcholine and carnitine resulted in the 
catabolism of choline via a microbiota-dependent mechanism 
to form: trimethylamine (TMA), and betaine (trimethyglyciene; 
TMG) (497), a molecule structurally similar to the amino acid 
glycine, but with three methyl groups (498). In the liver, TMA 
is oxidized into trimethylamine N-oxide (TMAO) (499), a small 
molecule strongly associated with promoting inflammatory-
based atherosclerosis (500, 501). Most of the bacteria that express 
genes encoding for TMA lyases are found in three of the four 
major phyla of the human gut microbiome (502). In apoliprotein 
E-deficient mice fed a diet with l-carnitine, the promotion of 
atherosclerosis was also mediated by a microbiota-dependent 
mechanism (501).
While higher plasma levels of l-carnitine, in association with 
TMAO, are positively correlated with cardiovascular events in 
humans, intriguingly, omnivores produce more TMAO from 
dietary l-carnitine than vegans or vegetarians (501). One 
plausible explanation for these observed differences can be 
in underlying archaeal lineages within the human gut micro-
biome. For instance, certain strains of methanogens, such as 
Methanomassiliicoccus luminyensis and Methanosarcina barkeri 
strictly use methyl-based compounds, including TMA, as 
substrates for methanogenesis to enable their growth, which 
can deplete TMA levels (503). M. luminyensis is a hydrogen-
dependent organism and member of the novel archaeal group 
Methanomassiliicoccales, and like other methanogens, capable 
of using methanol for methanogenesis (504). However, one 
remarkable feature of M.luminyensis is their ability to encode 
a rare proteinogenetic amino acid pyrrolysine (Pyl), a unique 
characteristic shared only by a limited number of other bacteria 
and some of the family Methanosarcinaceae (504). This is a truly 
distinguishing characteristic because methylotropic methano-
genesis of methylated amines, such as TMA, monomethylamine, 
and dimethylamine can only occur in the presence of pyrrolysine 
in the active catalytic site (505). Furthermore, studies exploring 
the abundance and activity of archaeal taxa have identified dif-
ferences in organism groups between human populations based 
on geography and dietary habits (e.g., salt-fermented seafood) 
(504, 506–511). The detection of Archaea in the vaginal flora of 
pregnant women also indicates critical mother-to-child “micro-
bial inheritance” (503, 512).
LiPiD-SOLUBLe viTAMiNS
vitamin A
Vitamin A is an essential dietary component that includes the 
group of unsaturated nutritional organic compounds retinol, 
retinal, retinoic acid, several pro-vitamin A carotenoids, and 
also beta carotene. Retinol is derived in the small intestine from 
retinyl palmitate, a vitamin A ester found in foods of animal 
origin, and in the body, can be converted to either retinal, or 
irreversibly to retinoic acid (496). The effects of vitamin A are 
employed via its genomic actions on a specific group of nuclear 
receptors, namely RXR and RAR (for which three isoforms 
exist). By comparison, retinoic acid participates in the activation 
of T cell lymphocytes (513–515), and CD103+ DCs migration 
from the lamina propria to mesenteric lymph nodes to promote 
Treg generation (516), and thereby extract non-pathogenic and 
pathogenic luminal bacteria (e.g., Salmonella typhimurium) by 
means of dendrite extension into the intestinal lumen (517). The 
lamina propria is also enriched with the IL-22-producing, IL3 
and Th17 cells (mostly small intestine), and retinoic acid pro-
motes enhanced resistance to experimental colitis by stimulating 
T cell production of IL-22  (518). Retinoic acid is also needed 
in utero for development of lymphoid tissue inducer cells (LTi) 
(519), a subset of retinoic acid receptor-related orphan recep-
tor (ROR)yt-dependent ILC3s, and an important contributor 
to innate immune development in intestinal tissues (520). In 
murine models, levels of vitamin A exposure during pregnancy 
influence the size of lymph nodes and Peyer’s patches, and in 
doing so determine immune competence in the next generation 
adult offspring (519, 521).
vitamin D
The VDR is abundantly expressed in both intestinal and all 
immune cells (522–525), with several lines of evidence impli-
cating vitamin D deficiency, or downregulation of the VDR, in 
the pathogenesis and severity of experimental IBD (522, 524, 
526–528). This process is now, in part, attributed to the barrier-
protecting role of VDR signaling in maintaining epithelial integ-
rity and its effect on gut microbiota composition (529). While the 
bioactive forms of vitamin D (1,25[OH]2D and 1,25[OH]2D3) 
activate the VDR to transcribe (or repress) at least 913 genes 
(530), VDR expression differs between genders, with females 
possessing an extra site of VDR gene expression (endometrium) 
(531). In addition, the bioactive forms of vitamin D are known to 
robustly increase the expression of some (e.g., NOD2) (532) – but 
not all – CD-associated susceptibility genes (533, 534), suggest-
ing its immunomodulatory activity to be vastly heterogeneous in 
nature. Recent evidence demonstrated that the anti-inflammatory 
effect of certain lactobacilli is via NOD2-mediated signaling 
(535), and that oral supplementation with Lactobacillus reuteri 
NCIMB 30242 can elicit increased concentrations of circulating 
25(OH)D (536).
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Under normal circumstances, a series of tightly controlled 
feedback pathways, namely the hepatic microsomal or mito-
chondrial enzyme 25-hydroxylase (catalyzed by CYP24A1) and 
the renal mitochondrial enzyme 1α-hydroxylase (catalyzed by 
CYP27B1), regulate the production and serum concentrations 
of 25(OH)D and 1,25(OH)2D, respectively, and in turn, VDR 
function (537, 538). The production of CYP24A1 is controlled 
by the VDR, whereas CYP27B1 production is controlled by 
immune-specific responses, with several cell types involved in 
innate and adaptive immune responses expressing CYP27B1 
(538–541). However, intestinal bacteria can also regulate 
intestinal expression of CYP27B1 (542), with VSL#3 treatment 
shown to induce VDR expression and activity in the host (543). 
The VDR plays a central role in regulating proteins involved 
in intracellular microbial recognition, namely TLRs and the 
anti-microbial proteins, human beta-defensin-2 (hBD-2) and 
cathelicidin, the latter known to progressively decline during 
CD over time (544, 545). Notably, mouse cells do not express 
the same cathelicidin gene as humans, and cellular response to 
active vitamin D differs, since murine cathelicidin (Cramp) lack 
the vitamin D response element (VDRE) (546).
Various microbes are able to evade the innate immune response 
by secreting VDR antagonists, allowing microbial survival 
within the cell, and modify human gene expression (547, 548). 
During pathogen-induced VDR dysregulation, VDR production 
of CYP24A1 decreases, resulting in low serum concentrations 
of 25(OH)D, consistent with the suboptimal vitamin D status 
commonly observed in CD patients (537). Over time, VDR 
activity, as well as the immune system, becomes increasingly 
compromised, and new pathogens are acquired by the host (548). 
There is also evidence that intestinal VDR can modulate hepatic 
bile acid synthesis, and that phytochemicals (e.g.,  curcumin) 
(549), and other dietary metabolites (e.g., butyrate) (550, 551), 
can bind to the VDR, thereby activating intestinal VDR 
target genes, including CYP3A family members (552–554). 
The likelihood of a VDR-dysregulating microbial commu-
nity in immune-mediated disorders is strengthened by data 
from VDR/CYB27B1-deficient mice, in which unregulated 
intestinal inflammation results in an environment conducive 
to phylum-level bacterial expansion within Proteobacteria, 
particularly species from the Desulfovibrionaceae family, with 
corresponding bacterial number reductions in Lachnospiraceae 
and Firmicutes phylum (555). One recent study demonstrated 
that VDR deficiency (VDR−/− mice) enriched Eggerthella (genus 
of Actinobacteria implicated in UC/CD) (556) in cecal stool, 
but depleted Alistipes and Odoribacter, whereas a depletion 
of Lactobacillus with markedly increased Clostridium and 
Bacteroides levels was observed in fecal stool (compared to 
WT mice) (557). Loss of VDR function also resulted in local 
enrichment related to synthesis and degradation of metabolites, 
namely fatty acids, glycans and LPS (557). Overall, taxonomic 
shifts such as these are thought to contribute to changes in the 
microbiome during inflammation, and similar alterations have 
been described in IBD patients compared with healthy controls 
(121, 289, 558–561). Patients treated with VDR antagonist 
(olmesartan) in conjunction with bacteriostatic antibiotics 
experience exacerbation of disease and immunopathology (562), 
indicating that VDR intricately mediates immune function, in 
part through gut microbiota.
THe COMPLeXiTY OF PANTROPiC 
iNTeRACTiONS BeTweeN MiCROBeS 
AND DieT
Macronutrients
Animal models using an isocaloric comparison between high-fat 
and low-fat diets require macronutrient displacement of carbohy-
drates by fats. Thus, the possibility exists that pro-inflammatory 
states are enhanced by a high-fat low-carbohydrate diet, which 
may lack dietary fibers needed to produce SCFAs. Few studies 
have investigated whether altering the dietary ratios of protein, 
carbohydrate, and fiber influences host response to a dietary 
fatty acid and/or bioactive compound (e.g., prebiotics, probiot-
ics). For instance, the beneficial, albeit species-specific effect, 
conferred by a probiotic to the host may be related to its fermen-
tation processes, and release of bioactive molecules; it is possible 
that fermentation products and bioactive molecules released by 
probiotic bacteria are dependent on the substrates available to 
them within the gut. Conceptually, this can apply to some, if not 
all, intestinal bacteria, but this is best studied in probiotics. The 
Lactobacillus helveticus R0052 is known for modulating inflam-
mation and gut microbiota structure in IL-10−/− mice (563, 564). 
However, outcomes depend on the diet consumed, mouse 
genotype and the presence of active inflammation, the latter 
correlates with gut microbiome alterations (565). IL-10−/− (129/
SvEv) mice fed a standard mouse chow (29% protein, 55% carbo-
hydrates, 13% fat; 3.8 kcal/g) or a Western style-diet (85% basal 
mix, non-hydrogenated lard, flax oil, sunflower oil; 28% protein, 
49% refined carbohydrate, 33% fat; 4.2 kcal/g), with or without 
L. helveticus R0052 for 21  days under SPF conditions (565), 
showed L. helveticus-mediated reversal of chronic microscopic 
lesions in IL-10−/− mice fed the Western diet, and major increase 
of IL-1β on regular chow. The L. helveticus also  reversed 
diet-induced increase of Proteobacteria abundance (E.coli, 
Salmonella) and increased Lentospirae.
Dietary fibers (pectin, guar gum, a mixture of both, or fiber-
free) are capable of mediating the pro-inflammatory potential 
of dietary lipids (566). Conventional rats fed a high-fat diet 
primarily reduced SCFA formation (compared to low-fat) with 
the guar gum group having significantly higher abundance of 
Bacteroidetes compared to other groups after 6  weeks (566). 
The fiber fiber-free group fed a high-fat had significantly higher 
abundance of Akkermansia, and higher MCP-1 concentrations 
to that of the guar gum group fed a high-fat diet for 2 and 
4  weeks (566). In rats, high-cholesterol diets (AIN76A w/w 
1% cholesterol), with soy in combination with fiber (psyllium, 
resistant maltodextrin and chicory powder), caused notable rise 
in abundance of Bacteroides spp., and reduction of Firmicutes: 
Bacteroidetes ratio, whereas soy alone increased the ratio partly 
due to a significant increase in Lactobacillus, Coproccus, and 
Blautia spp. (all Firmicutes) (567). Other studies have shown 
that potato-resistant starch attenuates the detrimental effects of a 
meat-based diet in mice by upregulating genes pivotal in colonic 
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barrier function and promoting higher numbers of beneficial 
Lactobacillus spp. (568, 569).
High-fat diets combined with high-sugar increased E.coli (AIEC) 
populations in transgenic carcinoembryonic antigen-related cell 
adhesion molecule 6 (CEABAC10) mice; leading to increased 
intestinal permeability, induction of NOD2 and TLR5 transcription, 
and TNFα secretion (570). By comparison, in mice fed a high-fat 
diet for 10 weeks and treated with coffee at 20 g/L with zero calorie 
sweetener aspartame added for taste (60 mg/L), coffee consumption 
not only attenuated the increase in Firmicutes: Bacteroidetes ratio 
and Clostridium Cluster XI but also resulted in increased levels of 
Enterobacteria (571). Coffee also increased serum levels of aromatic 
and circulating SCFAs, while lowering BCAAs. Clearly, confound-
ing effects may exist associated with adding aspartame as sweetener 
to the mix. However in another study, in which DSS-colitis-induced 
mice lacking expression of TLR5 by either intestinal epithelial cells 
[TLR5(DeltaIEC)] or DCs [TLR5(DeltaDC)] were examined for 
basal phenotypes in response to a high-fat diet and pathobiont chal-
lenge, microbiota composition was found to cluster more closely 
according to genotype than housing (572).
Phytochemicals
Approximately 90–95% of total dietary polyphenols reach the 
colon unabsorbed (573), and co-administration of quercetin 
was shown to enhance the anti-inflammatory properties of n-3 
PUFA in a DSS-colitis mouse model (574), implying that gut 
microbiota can indirectly influence (enhance or suppress) the 
effects of n-3 PUFA via the metabolism of phytochemicals avail-
able in the gut. Conversely, many functional foods, particularly 
those containing polyphenols and polyphenolic compounds, have 
the ability to influence the composition and metabolic activity of 
gut microbiota, although these outcomes are dose-dependent, 
and intimately reflect the chemical structure and form in which 
bioactive compounds are provided (i.e., whole foods vs. single 
bioactive), as this affects bioavailability, and derived physiological 
effects (575, 576). For example, distinct patterns in the prebiotic 
effects of four saponin-rich herbal teas (ginseng, red ginseng, 
notoginseng and gynostemma pentaphyllum) occur on gut micro-
biota composition in C57BL/6 mice (577). The effects of notogin-
seng were most prominent on Lactobacillus, although both red 
ginseng and gynostemma pentaphyllum increased abundance of F. 
prausnitzii, whereas gynostemma pentaphyllum resulted in strong-
est enhancement of Bifidobacterium at the species level (577). 
Another powerful phenolic compound, ellagic acid (ellagitannins) 
present in foods such as pomegranate, raspberries, blackberries, 
and strawberries has been recognized for modulating intestinal 
inflammation (578–582) and provides a rich source for ellagitan-
nin gut microbiota metabolites-urolithins (583–586).
Dietary emulsifiers
Dietary emulsifiers also impact gut microbiota community 
structure, with maltodextrin widely demonstrated for its ability to 
impair anti-bacterial cellular responses, reduce epithelial-barrier 
defense and directly affect multiple E.coli strains, including the 
promotion of AIEC colonization and cellular adhesion (587). 
Other additives include carboxymethycellulose (CMC or E466), 
polyscorbate-80 (P80 or E433), carrageenan, and xanthan gum. 
In an elaborate series of 12-week experiments, perturbations 
in IL-10−/−, TLR5−/− and wild-type C57BL/6 control mice gut 
microbiota composition were noted following exposure to CMC 
and P80 (dosages: 1, 0.1, 0.5%) (588–590). Both emulsifiers mark-
edly reduced microbial diversity in IL-10−/− mice, while fostering 
expansion of Proteobacteria and Verrucomimicobia phyla, par-
ticularly Akkermansia muciniphila (591, 592). In IL-10−/− mice 
(not TLR5−/− mice), emulsifier-induced colitis correlated with 
enrichments in Biophila and Helicobacter, consistent with previ-
ous observations in IL-10−/− mice (382, 593). Intriguingly, CMC 
and P80 also lead to alterations in both bile acid and fecal SCFA 
levels, including reductions in butyrate (593). It is important to 
note however, that dosages used were much higher than the prac-
tical human equivalent of 25 mg/kg body weight per day (594) 
and equated to a daily intake of 150,000 mg in a 60 kg adult. In 
addition, sodium sulfite was used as the control material for the 
emulsifiers. Sodium sulfite is added to various food and beverages 
(concentrations from 0.03 to 1.5 g/kg) as a preservative and as an 
antioxidant (595), but unlike emulsifiers, sodium sulfites are large 
hygroscopic molecules, not easily digested, which may increase 
fecal bulk (596). Sodium sulfite has been shown to impact compo-
sition and yield of fecal fiber, affect granular structure of resistant 
starches (597), and prevent the formation of lignans, correlating 
with lower recoveries of fecal neutral detergent fibers (598). 
Furthermore, after ingestion of sulfite-containing beverages, 
nitrite present in saliva from the oral cavity mixes with sulfite, 
and the mixture of salivary nitrate can then be transformed into 
NO with the gastric juice of the stomach (595).
Derived from several species of red seaweed (Rhodophyceae), 
carrageenans are various polysaccharides that differ in amount 
and distribution of sulfate groups, and widely used in processed 
foods to improve product viscosity and enhance texture of food 
products. Carrageenans are known activators of the B-cell leuke-
mia/lymphoma (Bcl10)-mediated TLR4 signaling pathways, and 
Bcl10 has been implicated as a key signaling molecule in most, 
but not all, carrageenan-initiated inflammatory pathways in 
epithelial cells (599). In animal models, ingestion of carrageenans 
predictably induce epithelial inflammation, with development of 
ulcerations and inflammatory infiltrates; however, inflammation 
is not suppressed in a GF environment, suggesting that colonic 
inflammation is not entirely bacterially driven (600–605). On the 
other hand, specific microflora, namely the two Lactobacillus spe-
cies L. casei and L. acidophilus, exerted anti-inflammatory effects 
on carrageenan-induced inflammatory responses, significantly 
downregulating pro-inflammatory cytokine pathways IL-6 and 
TNFα, while upregulating IL-10 (606). One study demonstrated 
that continual (25  weeks) prophylactic dietary supplemen-
tion with Aquamin, a mineral extract obtained from red algae 
Lithothamnion corallioides, ameliorated the serverity of sponta-
neous colitis in IL-10−/− mice on C57BL/6J background, but had 
no affect on IL-10−/− mice on a BALB/c background (607).
The unique structure of major matrix polysaccharides in the cell 
walls of red algae, the most common red seaweed polysaccharides 
present in carrageenans, requires a distinct set of gut microbiome-
encoded-enzymes known as carbohydrate active enzymes, or 
“CAZymes” (608, 609). CAZymes are predominantly encoded in 
genomes of marine microbes (610, 611), but absent in the human 
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genome, thus it was thought that humans cannot digest or absorb 
carrageenans (612). However, metagenomics studies have revealed 
genes encoding for CAZymes in members of the genus Bacteroides 
(e.g., B. plebeius), allowing additional sources of energy and 
nitrogen through bacterial degradation of specific carbohydrates 
(612, 613). This evolutionary adaptation appears to result from 
horizontal gene transfer, in that genes encoding for CAZymes 
which metabolize marine red algae, can be acquired by specific 
bacterial taxa in the human gut microbiome, from microbes living 
outside the gut, for instance, marine-associated bacteria (610, 612). 
Extrinsically acquired genes and their functions in the human gut 
microbiome warrants further investigations, considering the rising 
consumption of seaweeds, such as nori (species of red algae genus 
Porphyra), traditionally used to prepare sushi meals.
Succinic Acid
Succinic acid, an industrial food and beverage additive that regulates 
acidity, is also an end product of carbohydrate fermentation that acts 
as an inflammatory signal in immune cells to induce IL-1β through 
HIF-1α (transcription factor induced by hypoxia), a downstream 
target of succinate (614, 615). Succinate has the ability to stimulate 
ROS (616, 617), and succinate accumulation in immune cells acts as 
an inflammatory signal for macrophages, via HIF-1α (614). HIF-1α 
activation attenuates Treg development, induces IL-17 production 
and increases RORyt transcription, favoring differentiation of T lym-
phocytes into pro-inflammatory Th17 cells (618). Succinate is also 
a ligand for the succinate-receptor 1 (SUCNR1; formally GPCR91) 
expressed on DCs (615) and can enhance both pro-inflammatory 
cytokine (TNFα and Il-1β) production and the antigen presentation 
capacity of DCs, thereby inducing adaptive immune responses (615, 
619). In the colonic mucosa of rats, succinic acid lead to reduced 
crypt size and inhibition of epithelial cell proliferation rate (620). 
Notably, leptin is also a well-known HIF-1α-inducible modulator 
(621), with HIF-1α overexpression observed in obese adipose tis-
sue, and reduction during weight loss (118).
A CONCLUDiNG ReMARK ON DieTARY 
COMPLeXiTY
Clearly, animal models investigating the effects of single nutrient 
components are indispensable for our mechanistic understand-
ings of the gut microbiota. Thus, animals serve as a fundamental 
preclinical resource to understand the human gut microbiome. 
However, as the research continues to evolve, it is becoming 
clear that several basic diet-mediated pathways interact, and thus 
increasing efforts should be made to account for them to unveil 
novel mechanisms of sustained (diet/microbial-driven) inflam-
mation. The gut microbial community is also dependent on host 
genetics. In order to appropriately translate the experimental data 
into clinically viable recommendations and dosages, which are 
suitable for IBD, diet could be regarded as an “entity” and a sum of 
all individual components.
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